The market shift that’s changing everything
Precision medicine, orphan‑drug incentives and fast‑tracked biologics have flipped the traditional pharma‑supply equation on its head. Instead of blockbuster drugs that run for years, many launches now require only thousands or even hundreds of packs in total, often in multiple configurations and languages. Specialty drugs are the fastest‑growing segment of the market, creating a surge in demand for both small batches and low to medium volume projects.